vanutide cridificar (PF-236806) / J&J, Perrigo Company, Pfizer - LARVOL DELTA

Immunotherapeutic approaches for Alzheimer's disease: Exploring active and passive vaccine progress. (PubMed, Brain Res) - "ACC001 or PF05236806 vaccine has the same Aβ fragment and QS21 as an adjuvant. CAD106 stimulates response against Aβ1-6...AN1792, the first-generation vaccine was formulated in proinflammatory QS21 adjuvant...Immunotherapies have been at the forefront of these initiatives in recent years. The review covers the recent updates on active and passive immunotherapy for AD."

Journal • Review • Alzheimer's Disease • CNS Disorders • Dermatology • Infectious Disease

Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease (clinicaltrials.gov) - P2a; N=160; Completed; Sponsor: Pfizer; N=50 ➔ 160

Clinical • Enrollment change • Alzheimer's Disease • CNS Disorders

"Also thanks to my external #mentors, #coaches and sponsors including @roberthiggins32 @JFreischlag @DouglasEWood1 @ACC001 @TomVargheseJr @cllaucll2y @carriesims20 and countless others 6/" (@DavidCookeMD)

"Registration link on tweet below! #whyumichCTsurgery #whyumichsurgery @UMichSCRUBS @UMichMedAdmiss @UMichSurgery @ThoracicStudent @GAilawadiMD @ACC001 @jdimick1 @DLikosky @MikeTPhD @CBATS1 @UMichCHOPFellow" (@UMichCTSurgery)

"Ping @GAilawadiMD @ACC001 @KarenMKimMD1 @ShinFukuharaMD @BoYangMD @UMichSurgery @umichCVC @kiranlagisetty @ewakeam @JulesLin99 @DLikosky @MikeTPhD @jdimick1 @DavidCookeMD @TomVargheseJr @UMichCHOPFellow @UM_IHPI @UMichMedAdmiss @SocietyofBAS @AraVaporciyan @UMichCardiology" (@UMichCTSurgery)

Cardiovascular

"Ping @JessicaLuc1 @womeninsurgery @abribriesco43 @DavidCookeMD @ACC001 @ctsnetorg @UVA_TCV_Surgery @Hirji1987 @JasonHanMD @JordanBloomMD @CoyanGarrett @abmozer @claudenlouis @BrighamWomens @ABTS17 @EACTS @URMCSurgery @StanfordCTSurg @MarylandSurg @ColumbiaSurgery @WashUSurgery" (@TSRA_official)

Clinical

"We might be interested in this Bin! Can you send some details? @ACC001" (@ewakeam)

"And thank you to the @UMichCTSurgery community for their robust support!! @DLikosky @MikeTPhD @BoYangMD @ACC001 @kiranlagisetty @K_Kleeman @JulesLin99 @curtisbars" (@AlexBresciaMD)

"<24 hrs till this #CTCareers chat on building a digital presence! Brought to you by @STS_CTsurgery @CTSurgCareers Join in! @Doctor_V @meklingensmith @DrFBE @TheRakeshArora @arghavan_salles @clarongamd @CHarringtonMD @jonessurgery @ACSPastPrez98 @ACC001 @ScottReznik @pomyers" (@maraantonoff)

IMMUNOLOGICAL AGENTS FOR NEUROCOGNITIVE DISORDERS- A REVIEW OF THE CURRENT EVIDENCE (EPA 2019) - "Finished trials with published Results were investigating a tau vaccine (AADvac 1- positive Results , phase 1 trial) and several vaccines directed against beta-amyloid plaques (ACC-001- negative Results , two phase 2A trials, gantenerumab- it may be efficient, but more trials are needed, bapineuzumab failed, phase 3 trial, BAN2401- it was efficient in a single phase 2A trial, AN1792- phase 2A trial produced positive effects and a follow-up after 4.6 years detected low anti-AN1792 antibody titers, and CAD106- only a phase 1 trial). The level of evidence for current immunological therapies targeting AD is not very encouraging, but many trials are currently ongoing or will start in near future."